| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H20INO |
| Molecular Weight | 417.2834 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCN1C=C(C(=O)C2=CC=CC=C2I)C3=C1C=CC=C3
InChI
InChIKey=GAJBHYUAJOTAEW-UHFFFAOYSA-N
InChI=1S/C20H20INO/c1-2-3-8-13-22-14-17(15-9-5-7-12-19(15)22)20(23)16-10-4-6-11-18(16)21/h4-7,9-12,14H,2-3,8,13H2,1H3
| Molecular Formula | C20H20INO |
| Molecular Weight | 417.2834 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
AM-679 is a drug that acts as a moderately potent agonist for the cannabinoid receptors. AM-679 is a 5-lipoxygenase-activating protein inhibitor. AM-679, found in Italy for the first time, but also identified during a seizure made by Hungarian authorities, almost concurrent with the Italian seizure.
CNS Activity
Approval Year
PubMed
Patents
Sample Use Guides
AM-679 inhibits FLAP, as demonstrated in an in vitro human FLAP membrane binding assay with a 50% inhibitory concentration (IC50) of 2 nM and when assayed as an inhibitor of ex vivo ionophore-challenged mouse and human blood LTB4 synthesis with IC50s of 55 nM and 154 nM, respectively.
